Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure

Treatment of decompensated heart failure often includes administration of levosimendan. Myeloperoxidase (MPO) is released during polymorphonuclear neutrophil (PMN) degranulation, and mediates dysregulation of vascular tone in heart failure. We evaluated the effects of levosimendan-treatment on MPO i...

Descripción completa

Detalles Bibliográficos
Autores principales: Adam, Matti, Meyer, Sven, Knors, Henning, Klinke, Anna, Radunski, Ulf K., Rudolph, Tanja K., Rudolph, Volker, Spin, Joshua M., Tsao, Philip S., Costard-Jäckle, Angelika, Baldus, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394753/
https://www.ncbi.nlm.nih.gov/pubmed/25867530
http://dx.doi.org/10.1038/srep09704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394753/
https://www.ncbi.nlm.nih.gov/pubmed/25867530
http://dx.doi.org/10.1038/srep09704

Ejemplares similares